Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy.

摘要: 7588 Background: KRAS is one of the most commonly mutated oncogenes in non-small cell lung cancer (NSCLC). While impact EGFR mutations and EML4-alk translocations has been well-described, there limited information about these somatic on response to chemotherapy. Methods: We retrospectively reviewed demographics clinical outcomes patients with compared who were wild-type (WT). Eligible pts received 1st-line IV chemo for stage NSCLC at DFCI had known both status. Since biology we excluded such from analysis. The primary endpoint was progression-free survival (PFS) first-line chemo; secondary endpoints included radiographic rate (RR) overall (OS). Results: Between 2/05 8/11, 63 eligible 97 WT pts. groups similar age (median 65yrs ...